# NIPA1

## Overview
NIPA1 (non-imprinted in Prader-Willi/Angelman syndrome 1) is a gene that encodes the NIPA magnesium transporter 1, a transmembrane protein integral to cellular magnesium homeostasis. This protein is characterized by its nine transmembrane segments, which facilitate its localization to the plasma membrane and early endosomes, where it functions as a magnesium transporter (Zhao2008Hereditary; Botzolakis2011The). NIPA1 is also involved in the regulation of bone morphogenetic protein (BMP) signaling, interacting with the type II BMP receptor to modulate its endocytosis and degradation, thereby influencing axonal function and cellular signaling pathways (Tsang2009The). Mutations in NIPA1 are linked to neurodegenerative diseases such as Hereditary Spastic Paraplegia type 6 and amyotrophic lateral sclerosis, highlighting its clinical significance in neurological health (Blauw2012NIPA1; Zhao2008Hereditary).

## Structure
The NIPA1 protein is an integral membrane protein predicted to have 329 amino acids and nine transmembrane segments, which are crucial for its function as a magnesium transporter (Zhao2008Hereditary). These transmembrane domains facilitate the protein's localization to the plasma membrane and early endosomes, where it is primarily expressed (Botzolakis2011The). The protein is also found in the Golgi complex and synaptic vesicles, indicating a role in intracellular transport processes (Zhao2008Hereditary).

Mutations in NIPA1, such as T45R and G106R, are associated with hereditary spastic paraplegia and lead to mislocalization and accumulation of the protein in the endoplasmic reticulum (ER), suggesting a gain-of-function mechanism (Zhao2008Hereditary; Botzolakis2011The). These mutations do not significantly alter the overall expression levels but affect subcellular distribution, potentially causing cellular toxicity (Zhao2008Hereditary).

NIPA1 interacts with atlastin-1, another protein implicated in hereditary spastic paraplegia, forming hetero-complexes that are important for protein trafficking (Botzolakis2011The). Despite mutations, the interaction between NIPA1 and atlastin-1 remains intact, although their cellular distribution is altered (Botzolakis2011The).

## Function
The NIPA1 gene encodes a protein that functions as an intracellular magnesium transporter, playing a crucial role in maintaining cellular magnesium homeostasis. This protein is primarily localized to the plasma membrane and early endosomes, where it is involved in magnesium ion transport across cell membranes (Zhao2008Hereditary; Botzolakis2011The). NIPA1 is also found in the Golgi complex and synaptic vesicles, indicating its involvement in various cellular processes (Zhao2008Hereditary).

In healthy human cells, NIPA1 is implicated in the regulation of bone morphogenetic protein (BMP) signaling. It interacts with the type II BMP receptor (BMPRII), promoting its endocytosis and lysosomal degradation, thereby inhibiting BMP signaling pathways. This regulatory function is essential for maintaining distal axonal function, as dysregulation of BMP signaling is linked to axonopathy (Tsang2009The). NIPA1's activity in these processes is crucial for normal neurological function, as it helps modulate cellular signaling and maintain proper cellular function (Tsang2009The).

Overall, NIPA1's role in magnesium transport and BMP signaling highlights its importance in cellular and molecular processes that are vital for maintaining neurological health.

## Clinical Significance
Mutations in the NIPA1 gene are associated with several neurodegenerative diseases, most notably Hereditary Spastic Paraplegia type 6 (HSP6) and amyotrophic lateral sclerosis (ALS). HSP6 is characterized by progressive lower limb spasticity and weakness, often resulting from autosomal dominant mutations such as T45R and G106R, which lead to a gain-of-function mechanism causing neural degeneration (Zhao2008Hereditary; Chen2005Distinct). These mutations result in the accumulation of mutant NIPA1 protein in the endoplasmic reticulum, triggering ER stress and apoptosis (Zhao2008Hereditary).

In ALS, NIPA1 mutations, particularly polyalanine repeat expansions, are linked to increased disease susceptibility and influence the disease course. These expansions are associated with a higher odds ratio for disease susceptibility and earlier onset of symptoms (Blauw2012NIPA1). The presence of 'long' polyalanine repeat alleles in NIPA1 is correlated with shorter patient survival and earlier symptom onset (Blauw2012NIPA1).

Additionally, NIPA1 mutations have been implicated in the disruption of magnesium transport, which is crucial for neuronal health, further contributing to the pathogenesis of these neurodegenerative conditions (Fabbro2021A).

## Interactions
NIPA1 interacts with several proteins, playing a role in cellular processes and signaling pathways. It physically interacts with the bone morphogenetic protein receptor type II (BMPRII), promoting its endocytosis and lysosomal degradation. This interaction is independent of the intracellular tail sequences of BMPRII, suggesting that NIPA1 facilitates the trafficking of BMPRII to lysosomal compartments, thereby inhibiting BMP signaling (Tsang2009The).

NIPA1 also forms complexes with atlastin-1, another protein associated with hereditary spastic paraplegia. These proteins colocalize in cellular compartments such as the endoplasmic reticulum and Golgi complex. Their interaction is crucial for the proper trafficking of atlastin-1 to the cell surface, although NIPA1 can reach the cell surface independently. Mutations in NIPA1 and atlastin-1, which cause hereditary spastic paraplegia, alter their subcellular distribution but do not disrupt their interaction (Botzolakis2011The).

These interactions highlight NIPA1's role in modulating protein trafficking and signaling pathways, which are significant in understanding its function in hereditary spastic paraplegia and other cellular processes (Botzolakis2011The; Tsang2009The).


## References


[1. (Botzolakis2011The) Emmanuel J. Botzolakis, Jiali Zhao, Katharine N. Gurba, Robert L. Macdonald, and Peter Hedera. The effect of hsp-causing mutations in spg3a and nipa1 on the assembly, trafficking, and interaction between atlastin-1 and nipa1. Molecular and Cellular Neuroscience, 46(1):122–135, January 2011. URL: http://dx.doi.org/10.1016/j.mcn.2010.08.012, doi:10.1016/j.mcn.2010.08.012. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.mcn.2010.08.012)

[2. (Blauw2012NIPA1) Hylke M. Blauw, Wouter van Rheenen, Max Koppers, Philip Van Damme, Stefan Waibel, Robin Lemmens, Paul W. J. van Vught, Thomas Meyer, Claudia Schulte, Thomas Gasser, Edwin Cuppen, R. Jeroen Pasterkamp, Wim Robberecht, Albert C. Ludolph, Jan H. Veldink, and Leonard H. van den Berg. Nipa1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis. Human Molecular Genetics, 21(11):2497–2502, February 2012. URL: http://dx.doi.org/10.1093/hmg/dds064, doi:10.1093/hmg/dds064. This article has 51 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/dds064)

[3. (Zhao2008Hereditary) Jiali Zhao, Dawn S. Matthies, Emmanuel J. Botzolakis, Robert L. Macdonald, Randy D. Blakely, and Peter Hedera. Hereditary spastic paraplegia-associated mutations in thenipa1gene and itscaenorhabditis eleganshomolog trigger neural degenerationin vitroandin vivothrough a gain-of-function mechanism. The Journal of Neuroscience, 28(51):13938–13951, December 2008. URL: http://dx.doi.org/10.1523/jneurosci.4668-08.2008, doi:10.1523/jneurosci.4668-08.2008. This article has 39 citations.](https://doi.org/10.1523/jneurosci.4668-08.2008)

[4. (Chen2005Distinct) Suqin Chen, Chun Song, Hui Guo, Pingyi Xu, Weijun Huang, Yan Zhou, Jiandong Sun, Cai‐Xia Li, Yong Du, Xunhua Li, Zhuolin Liu, Deqin Geng, Patrick H. Maxwell, Cheng Zhang, and Yiming Wang. Distinct novel mutations affecting the same base in the nipa1 gene cause autosomal dominant hereditary spastic paraplegia in two chinese families. Human Mutation, 25(2):135–141, January 2005. URL: http://dx.doi.org/10.1002/humu.20126, doi:10.1002/humu.20126. This article has 54 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20126)

[5. (Tsang2009The) Hilda T.H. Tsang, Thomas L. Edwards, Xinnan Wang, James W. Connell, Rachel J. Davies, Hannah J. Durrington, Cahir J. O’Kane, J. Paul Luzio, and Evan Reid. The hereditary spastic paraplegia proteins nipa1, spastin and spartin are inhibitors of mammalian bmp signalling. Human Molecular Genetics, 18(20):3805–3821, July 2009. URL: http://dx.doi.org/10.1093/hmg/ddp324, doi:10.1093/hmg/ddp324. This article has 157 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddp324)

[6. (Fabbro2021A) Dora Fabbro, Catia Mio, Federico Fogolari, and Giuseppe Damante. A novel de novo nipa1 missense mutation associated to hereditary spastic paraplegia. Journal of Human Genetics, 66(12):1177–1180, June 2021. URL: http://dx.doi.org/10.1038/s10038-021-00941-x, doi:10.1038/s10038-021-00941-x. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s10038-021-00941-x)